Enhertu Gains FDA Approval as First-Line Treatment for HER2-positive Breast Cancer, Offering New Hope for patients
A notable advancement in breast cancer treatment has arrived. The Food and Drug Governance (FDA) recently approved Enhertu (trastuzumab deruxtecan) for use as a first-line therapy in adults battling unresectable or metastatic HER2-positive breast cancer. This marks a crucial shift, bringing a highly effective treatment option to patients earlier in their journey.
Alongside this approval, the FDA also greenlit two companion diagnostics. these tests will help doctors identify which patients are most likely to benefit from Enhertu,ensuring personalized and targeted care. Enhertu belongs to a powerful class of drugs called antibody-drug conjugates (ADCs), delivering chemotherapy directly to cancer cells.
A New Standard of Care Emerges
For years, the standard first-line treatment for HER2-positive breast cancer has been a combination of taxane chemotherapy, trastuzumab (Herceptin), and pertuzumab (Perjeta) – often referred to as THP. Now, Enhertu, particularly when combined with Perjeta, is poised to become a new standard.
This change is based on compelling results from a Phase 3 clinical trial. The study compared Enhertu alone,Enhertu plus Perjeta,and the traditional THP regimen.
Here’s what the data revealed:
* Progression-Free Survival: Patients receiving Enhertu plus Perjeta experienced a median progression-free survival of 40.7 months. This is significantly longer than the 26.9 months observed in patients treated with THP.
* Overall Survival: While overall survival data is still maturing (with 126 deaths reported across both arms), the initial findings are promising.
* Expert opinion: Dr. Sara Tolaney, a leading breast oncologist at Dana-Farber Cancer Institute and principal investigator of the study, believes Enhertu plus Perjeta should now be considered the new first-line standard for HER2-positive metastatic breast cancer.
Detailed findings were presented at the american Society of Clinical Oncology (ASCO) meeting and published in the New England Journal of Medicine earlier this year.
Enhertu’s Journey to First-Line Status
Enhertu’s path to this approval has been progressive. Initially approved in 2019 for third-line treatment, it moved to second-line use in 2022. This latest approval represents a major step forward, offering you a possibly more effective treatment option right from the start.
A Collaborative Effort & Growing Impact
Enhertu was originally discovered by Daiichi Sankyo. In 2019, AstraZeneca joined forces with Daiichi Sankyo to co-develop and commercialize the drug globally (with Daiichi Sankyo retaining full rights in japan).
The partnership has proven triumphant. In 2024, the companies reported combined Enhertu sales of $3.7 billion – a remarkable increase of over 46% from the previous year. following the U.S. approval for first-line use, Daiichi sankyo is set to receive a $150 million milestone payment from AstraZeneca.
What This Means for You
If you or a loved one is facing a diagnosis of HER2-positive metastatic breast cancer, this approval offers a reason for optimism. Talk to your oncologist about whether Enhertu, in combination with Perjeta, is the right treatment option for your specific situation.
This advancement underscores the ongoing progress in breast cancer research and the commitment to developing more effective, targeted therapies.
Image Credit: Public domain image by the National Cancer Institute (https://visualsonline.cancer.gov/details.cfm?imageid=2288).